Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab

Journal of Nuclear Medicine

Volumn 54, Issue 12, 2013, Pages 2062-2069

  Lastoria, Secondo ^a   Piccirillo, Maria Carmela ^a   Caracò, Corradina ^a   Nasti, Guglielmo ^a   Aloj, Luigi ^a   Arrichiello, Cecilia ^a   De Lutio Di Castelguidone, Elisabetta ^a   Tatangelo, Fabiana ^a   Ottaiano, Alessandro ^a   Iaffaioli, Rosario Vincenzo ^a   Izzo, Francesco ^a   Romano, Giovanni ^a   Giordano, Pasqualina ^a   Signoriello, Simona ^b   Gallo, Ciro ^b   Perrone, Francesco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Colorectal cancer; Early PET CT; Liver metastases; Predictive factor; Preoperative treatment

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; COLORECTAL LIVER METASTASIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIVER METASTASIS; MALE; MEDICAL PARAMETERS; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PREDICTIVE VALUE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; ADOLESCENT; COLORECTAL TUMOR; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; EARLY PET/CT; KAPLAN MEIER METHOD; LIVER METASTASES; LIVER TUMOR; METASTASIS; MIDDLE AGED; MULTIMODAL IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE FACTOR; PREOPERATIVE PERIOD; TIME; YOUNG ADULT; LIVER NEOPLASMS; SECONDARY;

COLORECTAL CANCER; EARLY PET/CT; LIVER METASTASES; PREDICTIVE FACTOR; PREOPERATIVE TREATMENT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PREOPERATIVE PERIOD; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84893393164     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.119909     Document Type: Article

References (40)

1. Kong G, Jackson C, Koh DM, et al. The use of 18F-FDG PET/CT in colorectal liver metastases: comparison with CT and liver MRI. Eur J Nucl Med Mol Imaging. 2008;35:1323-1329.
2. Ong KO, Leen E. Radiological staging of colorectal metastases. Surg Oncol. 2007;16:7-14.
3. Yang YY, Fleshman JW, Strasberg SM. Detection and management of extrahepatic colorectal cancer in patients with resectable liver metastases. J Gastrointest Surg. 2007;11:929-944.
4. Lejeune C, Bismuth MJ, Conroy T, et al. Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer. J Nucl Med. 2005;46:2020-2028.
5. Buck AK, Herrmann K, Stargardt T, et al. Economic evaluation of PET and PET/CT in oncology: evidence and methodological approaches. J Nucl Med. 2010;51:401-412.
6. Briggs RH, Chowdhury FU, Lodge JPA, Scarsbrook AF. Clinical impact of FDG PET-CT in patients with potentially operable metastatic colorectal cancer. Clin Radiol. 2011;66:1167-1174.
7. Weber WA. Positron emission tomography as an imaging biomarker. J Clin Oncol. 2006;24:3282-3292.
8. Larson SM, Schwartz LH. 18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology. J Nucl Med. 2006;47:901-903.
9. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107:52-59.
10. Kasamon YL, Wahl RL. FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma. Curr Opin Oncol. 2008;20:206-219.
11. Nasti G, Piccirillo MC, Izzo F, et al. Neoadjuvant FOLFIRI plus bevacizumab in patients with resectable liver metastasis from colorectal cancer: a phase II trial. Br J Cancer. 2013;108:1566-1570.
12. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma: clinicopathologic correlations. Cancer. 1994;73:2680-2686.
13. Hielscher T, Zucknick M, Werft W, Benner A. On the prognostic value of survival models with application to gene expression signatures. Stat Med. 2010;29:818-829.
14. Marubini E, Valsecchi MG. Analyzing Survival Data from Clinical Trials and Observational Studies. Chichester, U.K.: Wiley; 1995.
15. Kris MG, Meropol NJ, Winer EP, eds. Accelerating Progress Against Cancer: ASCO's Blueprint for Transforming Clinical and Translational Cancer Research. Available at: http://www.asco.org/sites/default/files/blueprint.pdf. Accessed October 8, 2013.
16. Booth CM, Eisenhauer EA. Progression-free survival: meaningful or simply measurable? J Clin Oncol. 2012;30:1030-1033.
17. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using 18-fluorodeoxyglucose positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer. 1999;35:1773-1782.
18. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50:122S-150S.
19. Hendlisz A, Golfinopoulos V, Garcia C, et al. Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. Ann Oncol. 2012;23:1687-1693.
20. Small RM, Lubezky N, Shmueli E, et al. Response to chemotherapy predicts survival following resection of hepatic colo-rectal metastases in patients treated with neoadjuvant therapy. J Surg Oncol. 2009;99:93-98.
21. Bertolini F, Malavasi N, Scarabelli L, et al. FOLFOX6 and bevacizumab in nonoptimally resectable liver metastases from colorectal cancer. Br J Cancer. 2011;104:1079-1084.
22. De Bruyne S, Van Damme N, Smeets P, et al. Value of DCE-MRI and FDG-PET/ CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases. Br J Cancer. 2012;106:1926-1933.
23. de Geus-Oei LF, van Laarhoven HWM, Visser EP, et al. Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. Ann Oncol. 2008;19:348-352.
24. Yanagawa M, Tatsumi M, Miyata H, et al. Evaluation of response to neoadjuvant chemotherapy for esophageal cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors. J Nucl Med. 2012;53:872-880.
25. Buvat I, Necib H, Garcia C, et al. Lesion-based detection of early chemosensitivity using serial static FDG PET/CT in metastatic colorectal cancer. Eur J Nucl Med Mol Imaging. 2012;39:1628-1634.
26. Larson SM, Erdi Y, Akhurst T, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolisis using PET-FDG imaging: the visual response and the change in total lesion glycolisis. Clin Positron Imaging. 1999;2:159-171.
27. Guillem JG, Moore HG, Akhurst T, et al. Sequential preoperative fluorodeoxyglucose- positron emission tomography assessment of response to preoperative chemoradiation: a means for determining long-term outcomes of rectal cancer. J Am Coll Surg. 2004;199:1-7.
28. Erdi YE, Macapinlac H, Rosenzweig KE, et al. Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med. 2000;27:861-866.
29. Akhurst T, Ng VV, Larson SM, et al. Tumor burden assessment with positron emission tomography with [18F] 2-fluoro 2-deoxyglucose (FDG PET) modelled in metastatic renal cell cancer. Clin Positron Imaging. 2000;3:57-65.
30. Benz MR, Allen-Auerbach MS, Eilber FC, et al. Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas. J Nucl Med. 2008;49:1579-1584.
31. Avallone A, Aloj L, Caracò C, et al. Early FDG PET response assessment of preoperative radiochemotherapy in locally advanced rectal cancer: correlation with long-term outcome. Eur J Nucl Med Mol Imaging. 2012;39:1848-1857.
32. Cascini GL, Avallone A, Delrio P, et al. 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. J Nucl Med. 2006;47:1241-1248.
33. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19:3058-3065.
34. Ott K, Fink U, Becker K, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol. 2003;21:4604-4610.
35. Lin C, Itti E, Haioun C, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med. 2007;48:1626-1632.
36. Capirci C, Rampin L, Erba PA, et al. Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy. Eur J Nucl Med Mol Imaging. 2007;34:1583-1593.
37. Francis RJ, Byrne MJ, van der Schaaf AA, et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med. 2007;48:1449-1458.
38. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst. 1994;86:829-835.
39. Takahashi R, Hirata H, Tachibana I, et al. Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung. Clin Cancer Res. 2012;18:220-228.
40. Cashen AF, Dehdashti F, Luo J, et al. 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. J Nucl Med. 2011;52:386-392.